Alphatec Holdings Director Keith Valentine Buys $243K of Stock
Keith Valentine, Director, bought 35,000 shares of Alphatec Holdings, Inc. at $6.93 a share, worth $243K in total on Nov 10, 2026. Shares held after the trade: 299,283 (+13.2%).
Alphatec Holdings Director David M. Demski Buys $409K of Stock
David M. Demski, Director, bought 60,000 shares of Alphatec Holdings, Inc. at $6.81 a share, worth $409K in total on Oct 30, 2026. Shares held after the trade: 491,635 (+13.9%).
Alphatec Holdings reported a significant reduction in net loss to $5.5 million for Q3 2026 compared to $28.6 million in the prior year, driven by a 12.6% increase in revenue to $221.2 million. The company achieved positive operating income of $3.2 million for the quarter, although it remains in a net loss position for the nine-month period ending September 30, 2026.
Alphatec Holdings reported Q3 2026 total revenue of $221 million, a 13% increase year-over-year, driven by 17% growth in surgical hardware revenue. Despite strong case volume growth of 20%, the company lowered its full-year 2026 revenue guidance to $862 million due to lower-than-expected biologics attachment.
Term
Q3 2026
“Third-quarter revenue fell short of our expectations, primarily due to lower biologics attachment. We own and are addressing that shortfall, and going forward, improving biologics performance is a clear priority for us. At the same time, we continued to see very strong demand for our procedural solutions, with hardware revenue growing 17%, case volumes growing approximately 20%, and new surgeon adoption increasing 25%.”